De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Harvard Bioscience Toekomstige groei
Future criteriumcontroles 0/6
Harvard Bioscience zal naar verwachting groeien in winst en omzet met respectievelijk 83% en 7.8% per jaar. De winst per aandeel zal naar verwachting groeien met 84.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -0.2% zijn.
Belangrijke informatie
83.0%
Groei van de winst
84.5%
Groei van de winst per aandeel
Life Sciences winstgroei | 17.6% |
Inkomstengroei | 7.8% |
Toekomstig rendement op eigen vermogen | -0.2% |
Dekking van analisten | Low |
Laatst bijgewerkt | 09 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 123 | 2 | 8 | 12 | 1 |
12/31/2025 | 107 | -3 | 4 | 7 | 2 |
12/31/2024 | 98 | -11 | -2 | 1 | 2 |
6/30/2024 | 101 | -11 | 6 | 9 | N/A |
3/31/2024 | 107 | -9 | 11 | 14 | N/A |
12/31/2023 | 112 | -3 | 12 | 14 | N/A |
9/30/2023 | 113 | -3 | 11 | 12 | N/A |
6/30/2023 | 114 | -5 | 7 | 9 | N/A |
3/31/2023 | 115 | -2 | 4 | 5 | N/A |
12/31/2022 | 113 | -10 | 0 | 1 | N/A |
9/30/2022 | 118 | -7 | -3 | -1 | N/A |
6/30/2022 | 121 | -4 | -4 | -3 | N/A |
3/31/2022 | 121 | -6 | -3 | -2 | N/A |
12/31/2021 | 119 | 0 | 0 | 1 | N/A |
9/30/2021 | 117 | -2 | 2 | 4 | N/A |
6/30/2021 | 111 | -3 | 5 | 6 | N/A |
3/31/2021 | 105 | -4 | 6 | 7 | N/A |
12/31/2020 | 102 | -8 | 8 | 9 | N/A |
9/30/2020 | 102 | -7 | 8 | 9 | N/A |
6/30/2020 | 105 | -8 | 9 | 11 | N/A |
3/31/2020 | 112 | -7 | 8 | 9 | N/A |
12/31/2019 | 116 | -5 | 7 | 8 | N/A |
9/30/2019 | 119 | -2 | 8 | 8 | N/A |
6/30/2019 | 120 | 0 | 3 | 4 | N/A |
3/31/2019 | 122 | -1 | 4 | 4 | N/A |
12/31/2018 | 121 | -4 | 2 | 3 | N/A |
9/30/2018 | 109 | -8 | -2 | -1 | N/A |
6/30/2018 | 99 | -8 | 2 | 3 | N/A |
3/31/2018 | 86 | -7 | N/A | 2 | N/A |
12/31/2017 | 77 | -2 | N/A | 1 | N/A |
9/30/2017 | 82 | -3 | N/A | 4 | N/A |
6/30/2017 | 88 | -4 | N/A | 5 | N/A |
3/31/2017 | 96 | -4 | N/A | 5 | N/A |
12/31/2016 | 105 | -4 | N/A | 5 | N/A |
9/30/2016 | 106 | -20 | N/A | 5 | N/A |
6/30/2016 | 107 | -19 | N/A | 2 | N/A |
3/31/2016 | 110 | -18 | N/A | 0 | N/A |
12/31/2015 | 109 | -19 | N/A | 1 | N/A |
9/30/2015 | 111 | -2 | N/A | 0 | N/A |
6/30/2015 | 110 | 0 | N/A | 1 | N/A |
3/31/2015 | 109 | 0 | N/A | 3 | N/A |
12/31/2014 | 109 | 2 | N/A | 4 | N/A |
9/30/2014 | 106 | 2 | N/A | 4 | N/A |
6/30/2014 | 106 | 1 | N/A | 5 | N/A |
3/31/2014 | 105 | 1 | N/A | 5 | N/A |
12/31/2013 | 105 | 1 | N/A | 4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat HBIO de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat HBIO de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat HBIO de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van HBIO ( 7.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van HBIO ( 7.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat HBIO binnen 3 jaar verliesgevend zal zijn.